Association of a *MET* genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression

L Heuer^{1,2}, D Braunschweig^{1,2}, P Ashwood^{2,3}, J Van de Water^{1,2} and DB Campbell^{4,5}

The contribution of peripheral immunity to autism spectrum disorders (ASDs) risk is debated and poorly understood. Some mothers of children with ASD have autoantibodies that react to fetal brain proteins, raising the possibility that a subset of ASD cases may be associated with a maternal antibody response during gestation. The mechanism by which the maternal immune system breaks tolerance has not been addressed. We hypothesized that the mechanism may involve decreased expression of the *MET* receptor tyrosine kinase, an ASD risk gene that also serves as a key negative regulator of immune responsiveness. In a sample of 365 mothers, including 202 mothers of children with ASD, the functional *MET* promoter variant rs1858830 C allele was strongly associated with the presence of an ASD-specific 37 + 73-kDa band pattern of maternal autoantibodies to fetal brain proteins ($P = 0.003$). To determine the mechanism of this genetic association, we measured *MET* protein and cytokine production in freshly prepared peripheral blood mononuclear cells from 76 mothers of ASD and typically developing children. The *MET* rs1858830 C allele was significantly associated with *MET* protein expression ($P = 0.025$). Moreover, decreased expression of the regulatory cytokine IL-10 was associated with both the *MET* gene C allele ($P = 0.001$) and reduced *MET* protein levels ($P = 0.002$). These results indicate genetic distinction among mothers who produce ASD-associated antibodies to fetal brain proteins, and suggest a potential mechanism for how a genetically determined decrease in *MET* protein production may lead to a reduction in immune regulation.

Translational Psychiatry (2011) 1, e48; doi:10.1038/tp.2011.48; published online 18 October 2011

Introduction

Autism spectrum disorders (ASDs) are a complex, behaviorally defined group of developmental disorders characterized by social deficits, language impairments and repetitive behaviors with restricted interests. Previous studies of twins and sibling recurrence risk have suggested that ASD is among the most heritable of neuropsychiatric disorders, encouraging extensive research into the genetic basis of ASD risk.^{1–3} However, a more recent twin study reported that susceptibility to ASD has a much lower genetic heritability component, while the more substantial component of risk was explained by environmental factors in a shared twin environment.⁴ This would indicate that the gestational environment, susceptible to genetic regulation by both the fetus and the mother, might be a major factor in determining ASD risk. The genetic risk may lie in (a) the direct impact of genetic regulation on brain development, (b) altering sensitivities to environmental factors and (c) disruption of autonomic and peripheral organ development and function that may influence brain development. In this regard, there is a growing body of evidence that, among risk factors, immune system dysregulation may be a feature in this neurodevelopmental disorder.^{5–7}

Growing evidence indicates that maternal immune dysfunction during gestation may contribute to ASD risk. In animal models, maternal immune activation during gestation leads to behavioral changes in subsequent offspring.⁸ In humans, epidemiologic analyses reported that a family history of autoimmune disorders was more common in families of children with ASD,^{9,10} and that immune-mediated disorders (psoriasis, maternal asthma and allergy) occurred more often around the time of pregnancy in the mothers of children with ASD compared with the mothers with typically developing (TD) children.¹¹ One early report demonstrated that serum from a mother of a child with ASD showed IgG antibody reactivity to rodent Purkinje cells; this same serum was then injected into gestating mice and shown to elicit behavioral deficits in the offspring.¹² In another study, 11 mothers of children with ASD and their affected children were found to have consistent patterns of antibody reactivity against rat prenatal brain proteins.¹³ Further studies have highlighted that this reactivity is to fetal and not adult brain proteins.¹⁴ Our recent studies have demonstrated reactivity against fetal brain proteins at ~37 and 73 kDa in plasma from 7 of 61 (11.5%) mothers of children with ASD but not in 102 mothers of TD children.¹⁵ Injection of rhesus monkeys with human IgG

¹Department of Internal Medicine, University of California, Davis, Davis, CA, USA; ²University of California, Davis M.I.N.D. Institute, Davis, CA, USA; ³Department of Medical Microbiology, University of California, Davis, Davis, CA, USA; ⁴Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁵Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Correspondence: Dr DB Campbell, 213 Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA or Dr J Van de Water, Division of Rheumatology/Allergy and Clinical Immunology; 451 E. Health Sciences Dr., Suite 6510; University of California Davis; Davis, CA 95616, USA.

E-mail: dbcampbe@usc.edu or javandewater@ucdavis.edu

Keywords: autism; gene; immune; maternal; cytokine

Received 21 June 2011; revised 2 September 2011; accepted 5 September 2011

from mothers of children with ASD (who were positive for fetal brain antibodies) during gestation resulted in increased stereotypical behavior and hyperactivity in the offspring when compared with the offspring of rhesus monkeys injected with IgG from mothers of TD children.¹⁶ Evidence of a potential role for these antibodies with respect to changes in neurodevelopment was also noted in a recent murine model.¹⁷

Although the preponderance of evidence points to an immune-mediated etiology in some cases of ASD, the biological mechanism of the maternal immune dysfunction remains unclear. In an independent line of study, we described robust genetic association with ASD of a functional variant in the 5' promoter of the gene encoding the *MET* receptor tyrosine kinase.¹⁸ The *MET* promoter variant, rs1858830, is a common G-to-C single-nucleotide polymorphism (SNP); the 'C' allele is inherited by individuals with ASD more often than predicted by chance and is more common in individuals with ASD than in a sample of the general population.^{18–20} Stratifying ASD subpopulations demonstrated that association of the *MET* 'C' allele is enriched in individuals with co-occurring ASD and gastrointestinal conditions,²¹ and in the social and communication domains of ASD.²² Independent evidence indicates decreased expression of the ligand for the *MET* receptor, hepatocyte growth factor (HGF), in serum of individuals with co-occurring ASD and gastrointestinal conditions.²³ In addition to its roles in brain development and gastrointestinal repair, the *MET* receptor tyrosine kinase is a key negative regulator of immune responsiveness. Ligation of the *MET* receptor by its HGF ligand prevents lupus nephritis in chronic graft-versus-host disease,²⁴ ameliorates the progression of experimental autoimmune myocarditis²⁵ and suppresses collagen-induced arthritis in mice.²⁶ *MET* also induces morphogenic changes in antigen-presenting cells. Importantly, *MET* signaling induces a tolerogenic phenotype in antigen-presenting cells through the induction of IL-10, without affecting their antigen-presenting capabilities.^{27,28} This tolerogenic phenotype induces T regulatory cells in response to antigen that would otherwise have broken tolerance and potentially lead to autoimmunity.²⁸ *MET* protein expression is decreased in postmortem brain of individuals with the *MET* 'C' allele.²⁹ If the same genotype–expression correlation is observed in the immune system, then one prediction is that disrupted *MET* signaling may confer susceptibility to immune dysregulation. We hypothesized that *MET* disruption would be associated with markers of immune dysregulation in mothers of children with ASD. To test this hypothesis, we examined the *MET* promoter variant rs1858830 'C' allele in the context of ASD-specific maternal antibodies to fetal brain proteins, as well as the cytokine profile of peripheral blood cells following immune challenge.

Materials and methods

Subjects. All mothers, ($n=365$) including those of children with an ASD ($n=202$) and those of TD control children ($n=163$), participated in the Childhood Autism Risks from Genetics and the Environment (CHARGE) study.³⁰ Those children enrolled in the study met the following criteria: (a)

they were between the ages of 24 and 60 months at the time of enrollment, (b) lived with at least one biologic parent, (c) had a parent who spoke either English or Spanish, (d) were born in the state of California and (e) resided in the catchment areas of a specified list of regional centers in Northern California. The CHARGE study is an ongoing population-based case–control study. This study protocol followed the ethical guidelines of the most recent Declaration of Helsinki, and was approved by the institutional review boards at the University of California, Davis, The State of California Department of Developmental Services, and the University of Southern California. Informed consent was obtained before participation.

To confirm the initial diagnosis, all children enrolled in the study were assessed at the UC Davis M.I.N.D. Institute. The diagnosis of ASD was confirmed in all subjects using the standardized Autism Diagnostic Interview–Revised (ADI–R)³¹ and the Autism Diagnostic Observation Schedule (ADOS) modules 1 or 2.^{32–35} The ADI–R provides a standardized, semi-structured interview and a diagnostic algorithm for the DSM-IV³⁶ and ICD-10 definitions of autism.³⁷ All of the CHARGE study clinical assessment personnel have attained research reliability on the ADI–R and the ADOS. The Social Communication Questionnaire was used to screen for behavioral and developmental characteristics of ASD among TD controls; children who scored above the screening cutoff score of 15 were fully assessed using the ADI–R and ADOS. Those controls that met criteria for autistic disorder were classified as ASD. Controls who did not meet criteria for ASD were classified as TD.

Autoantibodies. Western blot data collected and analyzed in a previous study was used for the association analyses described herein. Western blots were performed as previously described using fetal monkey brain extract.^{15,38}

Genotyping the ASD-associated *MET* promoter variant rs1858830. As the rs1858830 SNP falls within a highly GC-rich region, indirect genotyping methods fail when using genomic DNA. A 652-bp fragment containing the rs1858830 SNP was amplified from 15 ng genomic DNA with primers 5'-GATTTCCCTCTGGGTGGTG-3' (Forward) and 5'-CAAGC CCCATTCTAGTTTCG-3' (Reverse). Each 20- μ l reaction included 15 ng genomic DNA, 1 μ M each primer, 5% dimethyl sulfoxide, 15 mM MgCl₂, 0.25 mM each dNTP (dATP, dCTP, dGTP and dTTP), 2.5 U AmpliTaq Gold DNA Polymerase (ABI, Carlsbad, CA, USA) and 0.2 U Turbo pfu DNA polymerase (Stratagene, Santa Clara, CA, USA). Cycling conditions were: 95 °C for 5 min followed by 35 cycles of 95 °C for 30 s, 61 °C for 30 s and 72 °C for 1 min. Specific amplification of the 652-bp product was confirmed by agarose gel electrophoresis. Each PCR product was subjected to direct re-sequencing using an ABI 3730xl using Big Dye Terminator chemistry. Genotype at the *MET* rs1858830 locus was determined from the sequencing result using Sequencher software (Gene Codes, Ann Arbor, MI, USA).

Cell culture and stimulation. CHARGE is an ongoing study for which we have collected and banked both plasma

and DNA that allowed us to retroactively analyze subjects for both autoantibody production and genotype at the *MET* rs1858830 locus. However, cytokine production in response to immune challenge must be done on freshly isolated peripheral blood mononuclear cells (PBMCs). Therefore, a random subset of 76 mothers (22 C/C, 33 C/G and 21 G/G), prospective to study initiation, was used to assess the functional cytokine response in relation to *MET* rs1858830 genotype. Whole blood was collected through venipuncture into yellow top citrate tubes (BD, Franklin Lakes, NJ, USA) according to study protocol, and centrifuged at 900 *g* for 10 min to pellet cells. Plasma was collected and immediately frozen in 0.5 ml aliquots at -80°C until assayed by western blot for the presence of anti-fetal brain antibodies. The cell pellet was then adjusted to appropriate density with HBSS and layered over Histopaque density gradient (Sigma, St Louis, MO, USA) followed by centrifugation at 600 *g* for 30 min. The PBMC layer was removed and washed two additional times at 900 *g* for 10 min at which point cells were counted with a hemocytometer, and 300 000 cells per well were plated into 96-well round bottom plates. Cells were then allowed to rest 24 h before administration of $5\text{ }\mu\text{g ml}^{-1}$ lipopolysaccharide for 48 h to induce the production of an innate immune response. After stimulation, cell culture supernatants and cell pellets were frozen at -80°C until assayed for cytokine levels and *MET* protein levels, respectively.

Determination of cytokine levels. As a measure of innate immune reactivity following lipopolysaccharide stimulation, cell culture supernatants were analyzed for seven different cytokine and chemokines, including IL-6, GM-CSF, IL-1, IL-12p40, TNF- α , MIP-1 β and IL-10. Levels were determined using a commercially available multiplex bead-based kit and run according to manufacturer's instructions (Millipore, Billerica, MA, USA). Briefly, 25 μl of cell culture supernatant was incubated with anti-cytokine-conjugated beads in a 96-well filter-bottom plate on a plate shaker overnight at 4°C . The beads were then washed using a vacuum manifold, and biotin-conjugated detection antibodies were added for a 1-h incubation, followed by the subsequent addition of streptavidin-PE for 30 min. The plates were then read on a Bio-Plex 100 (BioRad, Hercules, CA, USA), and analyzed using Bio-Plex Manager software using a 5-point standard curve. Reference samples were run on each plate to determine assay consistency.

Determination of *MET* protein levels. After the supernatant was extracted, the cultured cells were used to determine the expression of the membrane-bound *MET* protein. The cell pellet was resuspended in 60- μl Novagen Widescreen protein extraction reagent. Protein assays were performed with the Luminex xMAP technology with a bead-based *MET* (HGF-Receptor) ELISA kit (Novagen, Rockland, MA, USA), by manufacturer's protocol. Briefly, the isolated protein was mixed with capture beads containing primary antibody directed to *MET* (HGF-Receptor; Novagen), followed by overnight shaking incubation at 4°C . Protein was measured on the Bio-Plex Suspension Array System (Bio-Rad, Hercules, CA, USA) at the Beckman Center Core

at the USC Norris Cancer Center. Data acquisition and analysis were performed using the Bio-Plex Manager software (Bio-Rad).

Statistical analyses. The χ^2 was used to analyze the association of *MET* rs1858830 genotype with the presence of maternal antibody. Allelic χ^2 results are presented; genotypic χ^2 results are similar. Genotype-dependent differences in *MET* protein and cytokine production were determined by analysis of variance followed by *post-hoc* Tukey–Kramer tests. Linear regression was used to determine correlation between *MET* protein expression and cytokine levels. Bonferroni correction for multiple comparisons was used to account for the analysis of multiple cytokines.

Results

Maternal antibody patterns associated with ASD risk. In a previous report with the CHARGE sample,³⁰ association with ASD risk was demonstrated for a 37 + 73-kDa band pattern of maternal antibodies reactive to fetal brain proteins in 61 mothers of children with ASD but not 102 mothers of TD children.¹⁵ Data for the current study were derived from an expanded study to include a total of 202 mothers of children with an ASD and 163 mothers of TD children.³⁸ Specificity of the combined 37 + 73-kDa band pattern with ASD risk was maintained in this larger sample. The 37 + 73-kDa band pattern (as illustrated in conjunction with Table 1) was present in 19 of 202 (9%) mothers of children with an ASD, and none of the 163 mothers of TD children (Table 1).

Association of *MET* rs1858830 C allele with ASD-associated maternal antibody band patterns. We next stratified the sample by maternal antibody patterns that have been shown to be associated with ASD risk in the offspring, and performed genetic association tests with the *MET* rs1858830 genotype. Among the 19 mothers who were positive for the 37 + 73-kDa band pattern, 11 (58%) were homozygous for the ASD-associated *MET* rs1858830 C allele, 7 (37%) were C/G heterozygotes and one (5%) was homozygous for the G allele (Table 2). Among the 183 mothers of children with ASD who were negative for the 37 + 73-kDa band pattern, 51 (28%) were C/C homozygous, 79 (43%) were C/G heterozygous and 53 (29%) were G/G homozygous (Table 2). This *MET* C allele frequency of 76% in the 19 mothers with the 37 + 73-kDa band pattern was significantly higher than the 49% C allele frequency observed

Table 1 Incidence of antibody reactivity to fetal brain proteins in mothers of children with an ASD compared with mothers of TD children

Diagnosis of offspring	N	Positive for 37/73-kDa band pattern (%)
ASD	202	19 (9)*
TD	163	0 (0)
ASD + TD	365	19 (5)

Abbreviations: ASD, autism spectrum disorder; TD, typically developing. Figure (B) illustrates the 37/73-kDa band pattern by western blot where lane 1 represents an antibody-positive mother of a child with an ASD, and lane 2 represents the mother of a TD control. * $P < 0.0001$ ASD vs TD.

Table 2 Association of *MET* rs1858830 C allele with the ASD-associated 37+73-kDa band pattern

37/73-kDa bands	N	<i>MET</i> C/C (%)	<i>MET</i> C/G (%)	<i>MET</i> G/G (%)	Allelic χ^2 P
ASD positive	19	11 (58)	7 (37)	1 (5)	Reference
ASD negative	183	51 (28)	79 (43)	53 (29)	0.002
ASD + TD negative	346	101 (29)	154 (45)	91 (26)	0.003

Abbreviations: ASD, autism spectrum disorder; TD, typically developing.

Figure 1 Association of *MET* rs1858830 genotype with MET protein expression in peripheral blood mononuclear cells (PBMCs). MET protein expression was reduced 1.4-fold in mothers of genotype C/C ($4.7 \pm 0.7 \text{ ng mg}^{-1}$ total protein) compared with mothers of genotype G/G ($6.7 \pm 0.8 \text{ ng mg}^{-1}$ total protein) ($P = 0.030$). MET protein expression was also decreased in mothers of genotype C/G compared with mothers of genotype G/G ($P = 0.025$). There was no significant difference in MET protein expression between mothers of genotype C/C and C/G ($P = 0.463$).

in the 183 mothers of children with ASD who did not exhibit the 37 + 73-kDa band pattern ($P = 0.002$; Table 2). Among 346 mothers of both ASD and TD children who were negative for the 37 + 73-kDa band pattern, 101 (29%) were C/C, 154 (45%) were C/G and 91 (26%) were G/G (Table 2). The 76% frequency of the *MET* C allele in mothers with the 37 + 73-kDa band pattern was also significantly higher than the 51% C allele frequency observed in all 346 mothers lacking the band pattern ($P = 0.003$; Table 2).

Association of *MET* rs1858830 genotype with MET protein levels in PBMCs of nonpregnant mothers. We previously reported an association of the *MET* C allele with decreased MET protein levels in postmortem brain samples from individuals with ASD.²⁹ To determine if *MET* rs1858830 genotype also predicts MET protein levels in peripheral blood, we measured MET protein levels in stimulated PBMCs isolated from 76 mothers of ASD and TD children, as MET is only expressed on immune cells in response to activation. As anticipated, results were similar to those observed in postmortem brain where the expression of MET protein was significantly reduced. In mothers with the *MET* rs1858830 C/C genotype, MET protein expression was reduced 1.4-fold in PBMCs compared with mothers with

Figure 2 Correlation of both *MET* rs1858830 genotype (a) and MET protein levels (b) with IL-10 expression in peripheral blood mononuclear cells (PBMCs). (a) IL-10 protein is increased 1.8-fold in G/G genotype mothers ($2295 \pm 321 \text{ ng mg}^{-1}$) compared with C/C genotype mothers ($1267 \pm 192 \text{ ng mg}^{-1}$) ($P = 0.001$). IL-10 protein is increased 1.6-fold in G/G genotype mothers compared with C/G genotype mothers ($1429 \pm 165 \text{ ng mg}^{-1}$) ($P = 0.005$). (b) Linear regression indicates highly significant correlation ($r = 0.401$; $P = 0.003$) between expression of MET protein and expression of IL-10 protein.

the G/G genotype ($P = 0.030$; Figure 1). MET protein was also significantly decreased in mothers with the C/G genotype compared with the G/G genotype ($P = 0.025$; Figure 1).

Correlation of both *MET* C allele and reduced MET protein levels with decreased cytokine IL-10 production in mothers. In the same PBMCs used for cellular MET protein level analysis, we also measured the production of seven cytokines (IL-1, IL-6, IL-10, IL-12(p40), GM-CSF, MIP-1 β and TNF- α) following stimulation with lipopolysaccharide of PBMC cultures. Production of the regulatory cytokine IL-10 was significantly associated with *MET* rs1858830 genotype and MET protein levels. The production of IL-10 was decreased 1.8-fold in mothers of genotype C/C compared with mothers of genotype G/G ($P = 0.001$; Figure 2a). As expected by the association of *MET* genotype to MET protein levels, the production of IL-10 was also positively correlated with the amount of MET protein ($P = 0.002$; Figure 2b). It is important to note that the significance of both of these results survive Bonferroni correction for analysis of seven analytes. The effect of *MET* genotype was specific to IL-10 as there was no correlation to expression of the other six cytokines tested.

Discussion

The results of this study suggest that the functional *MET* promoter variant rs1858830 C allele is associated with the presence of ASD-associated maternal antibodies to fetal brain proteins. The convergence of these two previously distinct associations with ASD risk (that of maternal antibodies to fetal brain proteins and of the *MET* C allele) provides the first link between an ASD susceptibility gene and a functional immune-related outcome to that gene.

MET is a receptor tyrosine kinase, serving different functions in distinct cell types, including proliferation, motogenesis, survival and differentiation. *MET* is best understood as an oncogene involved in the metastasis of several cancers: somatic gain-of-function mutations lead to dramatically increased signaling via the *MET* receptor, and uncontrolled cell proliferation and migration.³⁹ *MET* is also involved in mediating HGF signaling in a number of developmental, physiological and repair processes, including liver regeneration,⁴⁰ gastrointestinal repair,^{41–43} and in serving as a part of a negative feedback loop in immune responses.^{27,44,45} The *MET* C allele decreases transcription and results in reduced *MET* receptor tyrosine kinase protein in postmortem brain samples.^{18,29}

In the current study, we demonstrate that the *MET* C allele is also associated with decreased expression of *MET* protein in the immune system. As *MET* functions as a key negative regulator of immune function, the association of a functional genetic variant and ASD suggests a possible mechanism through which ASD-specific maternal antibodies to fetal brain proteins are generated. In addition to its role in autoimmunity, the *MET* receptor ligand HGF has also been shown to attenuate inflammatory conditions such as acute hyper responsiveness and airway remodeling in a murine model of asthma,⁴⁶ as well as the suppression of acute and chronic cardiac transplant rejection in the mouse.⁴⁷ While animal models lend support to an immunosuppressive role, the exact mechanism by which HGF exerts its effects on the immune system has not been fully elucidated. The *MET* receptor has been detected on monocytes/macrophages, dendritic cells and B cells, but not on T cells, even though HGF has been implicated in the adhesion and migration of memory T cells.^{27,44,48–51} Interestingly, *MET* protein expression is low to undetectable in inactive cells but increases dramatically in response to cellular activation.^{44,51} In this study, we provide evidence that subjects harboring the *MET* 'C' allele are deficient in a crucial immunoregulatory molecule, IL-10, that may leave them more susceptible to prolonged inflammatory conditions.

Figure 3 Proposed model of the mechanism by which maternal *MET* genotype predisposes, via immune dysregulation, toward neurodevelopmental alterations characteristic of ASD.

Interleukin-10 is a well-described immunosuppressive cytokine that has been shown to be upregulated in animal models, in which HGF is important in the prevention of autoimmunity.^{25,26,52} In addition, *in vitro* studies on the effects of HGF on both human and mouse antigen-presenting cells implicate IL-10 as a major contributor to the reported anti-inflammatory effects.^{28,53} IL-10 has been reported to be decreased in children with ASD compared with controls,^{54–56} but only in the context of innate cell activation. In the context of adaptive immune activation or at baseline, IL-10 levels in children with ASD are unchanged.^{57–61} However, there have not been any studies investigating the potential role of IL-10 dysregulation in the mothers of children with ASD.

In this study, we describe a decrease in levels of IL-10 that is significantly correlated with levels of MET protein expression. We had anticipated an increase in inflammatory cytokines as MET signaling has been shown to directly modulate the inflammatory response through phosphorylation of GSK3 β ; however, unlike other studies we did not observe a significant increase in pro-inflammatory cytokine production.⁵³ This is likely attributed to both the cellular composition of the stimulated cultures (the use of whole PBMC in our study vs the use of bone marrow-derived macrophages in animal studies) as well as the timing of cytokine measurements (48 vs 24 h). IL-10 is most often attributed with the resolution of an inflammatory response. It may be that signaling through the MET receptor functions to shorten the duration of the inflammatory response and not necessarily the magnitude, thereby allowing sustained inflammation in mothers with the *MET* 'C' allele. Such sustained inflammation would provide an environment conducive to loss of tolerance, thereby increasing the risk of autoantibody production, or potentiate a change in the cytokine profile during pregnancy that could negatively affect proper neurodevelopment (Figure 3).

A limitation of this study, and of our predicted model, is the lack of data indicating the factor responsible for initiation of the inflammatory response. While the *MET* 'C' allele may provide susceptibility toward reduced immune regulation, an environmental trigger such as infection, xenobiotic exposure or other stressor is still required to initiate an immune response. This may partially explain why the 'C' allele is evenly distributed among the population but is highly prevalent in mothers who exhibit markers of immune dysregulation, that is, autoantibody production. Future studies in a prospective model that will allow for tracking of environmental insults are needed to explore this mechanism in further detail.

Several studies have now addressed the potential role for maternal antibodies to fetal brain proteins in ASD.^{12–17,38} While each of these studies demonstrated both antibody specificity as well as a potential pathologic significance of the maternal autoantibodies, the current study is the first to present evidence suggesting a genetic polymorphism associated with the production of these antibodies. We fully acknowledge that no single gene or environmental factor will account for the entirety of ASD etiologies, and thus our focus on one ASD candidate gene, the MET receptor tyrosine kinase, was based on its bi-functional role in brain and immune development. Our observations that *MET* rs1858830 genotype predicts MET protein expression in the immune system, and that lower MET protein levels are correlated with

lower regulatory cytokine levels, provides mechanistic support for this focus. The studies described herein represent the beginning of our investigation into the potential mechanism(s) by which the maternal immune system becomes susceptible to the generation of antibodies to fetal brain tissue. Identification of a predisposing genetic factor such as MET will contribute greatly toward the understanding of the mechanisms involved in a subset of ASD cases.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgements. Shaine Jones, Nicole Grepo, Paul Duncanson and Kasey Rivas provided expert technical assistance. We gratefully acknowledge the resources provided by the Childhood Autism Risk due to Genetics and the Environment (CHARGE) Consortium and the participating CHARGE families. This work was supported in part by NIEHS 1P01ES11269-01 (JV, PA, LH and DB), US EPA Grant R829388 (JV and PA), NIEHS 1 R01-ES015359 (JV, PA and LH,) and the Autism Speaks Foundation (JV, DBC and PA).

- Gupta AR, State MW. Recent advances in the genetics of autism. *Biol Psychiatry* 2007; **61**: 429–437.
- Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. *Curr Opin Neurobiol* 2007; **17**: 103–111.
- Levitt P, Campbell DB. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. *J Clin Invest* 2009; **119**: 747–754.
- Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T et al. Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen Psychiatry* 2011 Jul 4.
- Ashwood P, Van de Water J. A review of autism and the immune response. *Clin Dev Immunol* 2004; **11**: 165–174.
- Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. *J Leukoc Biol* 2006; **80**: 1–15.
- Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mimics K et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. *Neurobiol Dis* 2008; **30**: 303–311.
- Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. *Brain Behav Immun* 2010; **24**: 881–897.
- Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. *J Child Neurol* 1999; **14**: 388–394.
- Atladóttir HO, Thorsen P, stergaard L, Schendel DE, Lemcke S, Abdallah M et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. *J Autism Dev Disord* 2010; **40**: 1423–1430.
- Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. *Arch Pediatr Adolesc Med* 2005; **159**: 151–157.
- Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J et al. Maternal neuronal antibodies associated with autism and a language disorder. *Ann Neurol* 2003; **53**: 533–537.
- Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA et al. Maternal antibody to brain proteins in autism. *Brain Behav Immun* 2007; **21**: 351–357.
- Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mothers with autistic children. *J Neuroimmunol* 2008; **194**: 165–172.
- Braunschweig D, Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen LA et al. Autism: maternally derived antibodies specific for fetal brain proteins. *Neurotoxicology* 2008; **29**: 226–231.
- Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypes and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. *Brain Behav Immun* 2008; **22**: 806–816.
- Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. *J Neuroimmunol* 2009; **211**: 39–48.
- Campbell DB, Sutcliffe JS, Ebert PJ, Milneri R, Bravaccio C, Trillo S et al. A genetic variant that disrupts MET transcription is associated with autism. *Proc Natl Acad Sci USA* 2006; **103**: 16834–16839.
- Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. *Autism Res* 2008; **1**: 158–168.

20. Jackson PB, Boccuto L, Skinner C, Collins JS, Neri G, Gurrieri F et al. Further evidence that the rs1858830 C variant in the promoter region of the *MET* gene is associated with autistic disorder. *Autism Res* 2009; **2**: 232–236.
21. Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM et al. Distinct genetic risk based on association of *MET* in families with co-occurring autism and gastrointestinal conditions. *Pediatrics* 2009; **123**: 1018–1024.
22. Campbell DB, Warren D, Sutcliffe JS, Lee EB, Levitt P. Association of *MET* with social and communication phenotypes in individuals with autism spectrum disorder. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**: 438–446.
23. Russo AJ, Krigsman A, Jepson B, Wakefield A. Decreased serum hepatocyte growth factor (HGF) in autistic children with severe gastrointestinal disease. *Biomark Insights* 2009; **4**: 181–190.
24. Kuroiwa T, Iwasaki T, Imado T, Sekiguchi M, Fujimoto J, Sano H. Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft-versus-host disease. *Arthritis Res Ther* 2006; **8**: R123.
25. Futamatsu H, Suzuki J, Mizuno S, Koga N, Adachi S, Kosuge H et al. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. *Circ Res* 2005; **96**: 823–830.
26. Okunishi K, Dohi M, Fujio K, Nakagome K, Tabata Y, Okasora T et al. Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. *J Immunol* 2007; **179**: 5504–5513.
27. Okunishi K, Dohi M, Nakagome K, Tanaka R, Mizuno S, Matsumoto K et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. *J Immunol* 2005; **175**: 4745–4753.
28. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10+IL-12low/neg accessory cells with dendritic-cell features. *Blood* 2006; **108**: 218–227.
29. Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mimics K, Levitt P et al. Disruption of cerebral cortex *MET* signaling in autism spectrum disorder. *Ann Neurol* 2007; **62**: 243–250.
30. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ Health Perspect* 2006; **114**: 1119–1125.
31. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. *J Autism Dev Disord* 1997; **27**: 501–517.
32. DiLavore PC, Lord C, Rutter M. The pre-linguistic autism diagnostic observation schedule. *J Autism Dev Disord* 1995; **25**: 355–379.
33. Joseph RM, Tager-Flusberg H, Lord C. Cognitive profiles and social-communicative functioning in children with autism spectrum disorder. *J Child Psychol Psychiatry* 2002; **43**: 807–821.
34. Lord C, Leventhal BL, Cook Jr EH. Quantifying the phenotype in autism spectrum disorders. *Am J Med Genet* 2001; **105**: 36–38.
35. Owley T, McMahon W, Cook EH, Lauhere T, South M, Mays LZ et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. *J Am Acad Child Adolesc Psychiatry* 2001; **40**: 1293–1299.
36. APA. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV*. 4th edn American Psychiatric Association: Washington, DC, 1994.
37. Steinhausen HC, Erdin A. Abnormal psychosocial situations and ICD-10 diagnoses in children and adolescents attending a psychiatric service. *J Child Psychol Psychiatry* 1992; **33**: 731–740.
38. Braunschweig D, Duncanson P, Boyce R, Hansen R, Ashwood P, Pessah I et al. Behavioral correlates of maternal antibody status among children with autism. *J Autism Dev Disord* 2011 (in press).
39. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003; **4**: 915–925.
40. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. *Proc Natl Acad Sci USA* 2004; **101**: 4477–4482.
41. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. *J Pharmacol Exp Ther* 2003; **307**: 146–151.
42. Arthur LG, Schwartz MZ, Kuenzler KA, Birbe R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. *J Pediatr Surg* 2004; **39**: 139–143; discussion 139–143.
43. Ido A, Numata M, Kodama M, Tsubouchi H. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. *J Gastroenterol* 2005; **40**: 925–931.
44. Beilmann M, Odenthal M, Jung W, Vande Woude GF, Dienes HP, Schirmacher P. Neoeexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. *Blood* 1997; **90**: 4450–4458.
45. Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P. Hepatocyte growth factor-stimulated invasiveness of monocytes. *Blood* 2000; **95**: 3964–3969.
46. Ito W, Kanehiro A, Matsumoto K, Hirano A, Ono K, Maruyama H et al. Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling. *Am J Respir Cell Mol Biol* 2005; **32**: 268–280.
47. Yamaura K, Ito K, Tsukioka K, Wada Y, Makiuchi A, Sakaguchi M et al. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. *Circulation* 2004; **110**: 1650–1657.
48. Adams DH, Harvath L, Bottaro DP, Interrante R, Catalano G, Tanaka Y et al. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. *Proc Natl Acad Sci USA* 1994; **91**: 7144–7148.
49. Chen Q, DeFrances MC, Zarnegar R. Induction of met proto-oncogene (hepatocyte growth factor receptor) expression during human monocyte-macrophage differentiation. *Cell Growth Differ* 1996; **7**: 821–832.
50. van der Voort R, Taher TE, Keehn RM, Smit L, Groenink M, Pals ST. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. *J Exp Med* 1997; **185**: 2121–2131.
51. Galimi F, Cottone E, Vigna E, Arena N, Boccaccio C, Giordano S et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. *J Immunol* 2001; **166**: 1241–1247.
52. Benkhoucha M, Santiago-Raber M-L, Schneiter G, Chofflon M, Funakoshi H, Nakamura T et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. *Proc Natl Acad Sci USA* 2010; **107**: 6424–6429.
53. Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. *PLoS ONE* 2010; **5**: e15384.
54. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. *J Neuroimmunol* 2006; **173**: 126–134.
55. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. *Neuropsychobiology* 2005; **51**: 77–85.
56. Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. *J Neuroinflammation* 2008; **5**: 52.
57. Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P et al. Elevated cytokine levels in children with autism spectrum disorder. *J Neuroimmunol* 2006; **172**: 198–205.
58. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li X-M et al. Elevated immune response in the brain of autistic patients. *J Neuroimmunol* 2009; **207**: 111–116.
59. Gupta S, Aggarwal S, Roshanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. *J Neuroimmunol* 1998; **85**: 106–109.
60. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. *Neuropsychobiology* 2002; **45**: 1–6.
61. Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F et al. Low-grade endotoxemia in patients with severe autism. *Neurosci Lett* 2010; **471**: 162–165.

Translational Psychiatry is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>